Physician profile
David Rovinsky
NPI 1528163284
$1,113,874.54
in general payments reported to CMS, 2019-2025
5 companies · $115K in 2025
The $115K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277K · 2020: $132K · 2021: $84K · 2022: $74K · 2023: $144K · 2024: $288K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $152K · Royalty Or License: $144K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Travel and Lodging: $93K · Acquisitions: $13K · Food and Beverage: $5,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $151,925.00 |
| Royalty Or License | $143,950.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140,840.00 |
| Travel and Lodging | $92,717.38 |
| Acquisitions | $12,881.17 |
| Food and Beverage | $5,333.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $930,536.41 | 2019-2025 | Real Intelligence, Journey II, Legion Revision |
| Zimmer Biomet Holdings, INC. | $182,692.95 | 2024-2025 | |
| Orthalign INC | $364.23 | 2019 | |
| Depuy Synthes Sales INC. | $225.35 | 2019-2025 | Na, Va-Lcp, Tfn-Advance |
| Axogen | $55.60 | 2024 | Axoguard Nerve Protector, Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rovinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.